The Customer
Artificial intelligence powered synthetic biology company
The Challenge
- Company looking to preserve cash within a challenged market of raising capital
- Company had very little revenue. Company was waiting to recognize milestone payments from their customer’s drug submission.
Done Deal.
- FNC approved $8,000,000 in financing for various lab and testing equipment.
- FNC was growing tremendously and was looking to preserve equity prior to the company filing for their public offering
- FNC was able to replenish cash from prior purchases via a sale leaseback and add a capex loc to fund all future equipment.
- FNC understood the nature of the industry and leveraged the balance sheet to structure a deal that was favorable for both parties.
Business Cycle Volatility
Wider credit appetite for companies in all phases of the business cycle.
